Skip to content
2000
image of miRNA-29b-3p: An Important Target for Ameliorating Liver Fibrosis in Wilson Disease by Inhibiting Autophagy

Abstract

Background

Liver fibrosis is an important pathological feature of Wilson disease (WD). The miRNA-29b-3p level decreased in liver fibrosis, while the mechanism of miRNA-29b-3p in liver fibrosis has not been reported, and was elucidated in the work.

Methods

The miRNA-29b-3p levels were evaluated by q-PCR. The effect of miRNA-29b-3p on the activity of hepatic stellate cells was detected by cell activity assay. The protein levels were checked by western blot. The interaction between miRNA-29b-3p and ULK1 mRNA with base complementary sequences was detected by double luciferase assay. The autophagosomes were observed by TEM. The cell fibrosis-like change was evaluated with an anti-α-smooth muscle actin (α-SMA) antibody by IF.

Results

The results showed that miRNA-29b-3p mimics down-regulated the α-SMA and Col1 protein levels, and miRNA-29b-3p inhibitors upregulated the α-SMA and Col1 protein levels. The dual-luciferase assay result revealed that miRNA-29b-3p interacted with ULK1. The miRNA-29b-3p mimics inhibited the protein expression of ULK1, beclin1, and LC3, whereas miRNA-29b-3p inhibitors promoted the protein expression of ULK1, beclin1, and LC3.

Conclusion

The miRNA-29b-3p blocked HSCs trans-differentiation into myofibroblasts by inhibiting autophagy, and further inhibiting liver fibrosis in WD.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmm/10.2174/0115665240373925250510072405
2025-05-14
2025-09-14

  • From This Site

    /content/journals/cmm/10.2174/0115665240373925250510072405
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Dong Y. Ni W. Chen W.J. Wan B. Zhao G.X. Shi Z.Q. Zhang Y. Wang N. Yu L. Xu J.F. Wu Z.Y. Spectrum and classification of ATP7B variants in a large cohort of Chinese Patients with Wilson’s disease guides genetic diagnosis. Theranostics 2016 6 5 638 649 10.7150/thno.14596 27022412
    [Google Scholar]
  2. Shribman S. Poujois A. Bandmann O. Czlonkowska A. Warner T.T. Wilson’s disease: Update on pathogenesis, biomarkers and treatments. J. Neurol. Neurosurg. Psychiatry 2021 92 10 1053 1061 10.1136/jnnp‑2021‑326123 34341141
    [Google Scholar]
  3. Christopher J C Fan Y Remwilyn D Direct measurement of ATP7B peptides is highly effective in the diagnosis of Wilson disease. Gastroenterology 2021 160 7 2367 2382 10.1053/j.gastro.2021.02.052 33640437
    [Google Scholar]
  4. Thomas Damgaard S. Tea Lund L. Ditte Emilie M. The prevalence of Wilson's disease: An update. Hepatology 2020 71 2 722 732 10.1002/hep.30911 31449670
    [Google Scholar]
  5. Zhang S. Yang W. Li X. Pei P. Dong T. Yang Y. Zhang J. Clinical and genetic characterization of a large cohort of patients with Wilson’s disease in China. Transl. Neurodegener. 2022 11 1 13 10.1186/s40035‑022‑00287‑0 35220961
    [Google Scholar]
  6. Roberts E.A. Schilsky M.L. Current and emerging issues in Wilson’s disease. N. Engl. J. Med. 2023 389 10 922 938 10.1056/NEJMra1903585 37672695
    [Google Scholar]
  7. Samuel S Thomas M Abubakar S Investigation and management of Wilson's disease: A practical guide from the British association for the study of the liver. Lancet Gastroenterol Hepatol 2022 7 6 560 575 10.1016/S2468‑1253(22)00004‑8 35429442
    [Google Scholar]
  8. Teschke R. Eickhoff A. Wilson disease: Copper-mediated cuproptosis, iron-related ferroptosis, and clinical highlights, with comprehensive and critical analysis update. Int. J. Mol. Sci. 2024 25 9 4753 10.3390/ijms25094753 38731973
    [Google Scholar]
  9. Güngör Ş. Selimoğlu M.A. Varol F.İ. Güngör S. Pediatric Wilson’s disease: Findings in different presentations. A cross-sectional study. Sao Paulo Med. J. 2018 136 4 304 309 10.1590/1516‑3180.2018.0210230718 30304203
    [Google Scholar]
  10. Lianjie L. Dongxu W. Nannan D. Changqing Z. Hepatic manifestations in Wilson's disease: Report of 110 cases. Hepatogastroenterology 2015 May 62 139 657 660 26897948
    [Google Scholar]
  11. Michael L.S. Eve A.R. Jeff M.B. A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American association for the study of liver diseases. Hepatology 2022 77 4 1428 1455 36152019
    [Google Scholar]
  12. Huang C.C. Wilson's disease: Clinical analysis of 71 cases and comparison with previous Chinese series. J Formos Med Assoc 1992 91 5 502 507 1358328
    [Google Scholar]
  13. Oliver B. Karl Heinz W. Stephen G.K. Wilson's disease and other neurological copper disorders. Lancet Neurol 2015 14 1 103 113 10.1016/S1474‑4422(14)70190‑5 25496901
    [Google Scholar]
  14. Lorincz M.T. Neurologic Wilson’s disease. Ann. N. Y. Acad. Sci. 2010 1184 1 173 187 10.1111/j.1749‑6632.2009.05109.x 20146697
    [Google Scholar]
  15. Chevalier K. Mauget-Faÿsse M. Vasseur V. Azar G. Obadia M.A. Poujois A. Eye involvement in Wilson’s disease: A review of the literature. J. Clin. Med. 2022 11 9 2528 10.3390/jcm11092528 35566651
    [Google Scholar]
  16. Golding D.N. Walshe J.M. Arthropathy of Wilson’s disease. Study of clinical and radiological features in 32 patients. Ann. Rheum. Dis. 1977 36 2 99 111 10.1136/ard.36.2.99 857745
    [Google Scholar]
  17. Agrawal A.K. Haddad F.G. Matsunaga A. Acute nonimmune hemolytic anemia without fulminant hepatitis in Wilson disease. J. Pediatr. Hematol. Oncol. 2011 33 4 e163 e165 10.1097/MPH.0b013e3182122422 21516016
    [Google Scholar]
  18. Loudianos G. Satta S. Lepori M.B. Anni F. Balloi R. Soddu C. Fenu M.L. Lilliu F. Nurchi A.M. De Virgiliis S. Wilson’s disease in Sardinian population: The experience of a pediatric referral center. J. Pediatr. Gastroenterol. Nutr. 2024 79 4 807 817 10.1002/jpn3.12343 39113473
    [Google Scholar]
  19. Dong Y. Wu Z.Y. Challenges and suggestions for precise diagnosis and treatment of Wilson’s disease. World J. Pediatr. 2021 17 6 561 565 10.1007/s12519‑021‑00475‑4 34714531
    [Google Scholar]
  20. Socha P. Czlonkowska A. Janczyk W. Litwin T. Wilson’s disease- management and long term outcomes. Best Pract. Res. Clin. Gastroenterol. 2022 56-57 101768 10.1016/j.bpg.2021.101768 35331405
    [Google Scholar]
  21. Vieira Barbosa J. Fraga M. Saldarriaga J. Hiroz P. Giostra E. Sempoux C. Ferenci P. Moradpour D. Hepatic manifestations of Wilson’s disease: 12-year experience in a Swiss tertiary referral centre. Swiss Med. Wkly. 2018 148 w14699 10.4414/smw.2018.14699 30576569
    [Google Scholar]
  22. Wen-Jie L. Huan-Ling C. Bin W. Wilson’s disease: Food therapy out of trace elements. Front. Cell Dev. Biol. 2023 10 1091580 10.3389/fcell.2022.1091580
    [Google Scholar]
  23. Garoufalia Z. Prodromidou A. Machairas N. Kostakis I.D. Stamopoulos P. Zavras N. Fouzas I. Sotiropoulos G.C. Liver transplantation for Wilson’s disease in non-adult patients: A systematic review. Transplant. Proc. 2019 51 2 443 445 10.1016/j.transproceed.2019.01.017 30879562
    [Google Scholar]
  24. Xiang-Zhen Y. Ren-Min Y. Xiao-Ping W. Management perspective of Wilson’s disease: Early diagnosis and individualized therapy. Curr. Neuropharmacol. 2020 19 4 465 485 10.2174/1570159X18666200429233517 32351182
    [Google Scholar]
  25. Alqahtani S.A. Chami R. Abuquteish D. Vandriel S.M. Yap C. Kukkadi L. Parmar A. Mundh A. Roberts E.A. Kamath B.M. Siddiqui I. Hepatic ultrastructural features distinguish paediatric Wilson disease from NAFLD and autoimmune hepatitis. Liver Int. 2022 42 11 2482 2491 10.1111/liv.15319 35603480
    [Google Scholar]
  26. Uta M. Isabelle M. Hereditary liver diseases: Wilson's disease and hemochromatosis. Dtsch. Med. Wochenschr. 2023 148 148 836 843 10.1055/a‑1871‑6393 37364578
    [Google Scholar]
  27. Cheng C. Wang Q. Huang Y. Xue Q. Wang Y. Wu P. Liao F. Miao C. Gandouling inhibits hepatic fibrosis in Wilson’s disease through Wnt-1/β-catenin signaling pathway. J. Ethnopharmacol. 2023 311 116445 10.1016/j.jep.2023.116445 37015279
    [Google Scholar]
  28. Arroyo N. Villamayor L. Díaz I. Carmona R. Ramos-Rodríguez M. Muñoz-Chápuli R. Pasquali L. Toscano M.G. Martín F. Cano D.A. Rojas A. GATA4 induces liver fibrosis regression by deactivating hepatic stellate cells. JCI Insight 2021 6 23 e150059 10.1172/jci.insight.150059 34699385
    [Google Scholar]
  29. Higashi T. Friedman S.L. Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv. Drug Deliv. Rev. 2017 121 27 42 10.1016/j.addr.2017.05.007 28506744
    [Google Scholar]
  30. Dou C. Liu Z. Tu K. Zhang H. Chen C. Yaqoob U. Wang Y. Wen J. van Deursen J. Sicard D. Tschumperlin D. Zou H. Huang W.C. Urrutia R. Shah V.H. Kang N. P300 acetyltransferase mediates stiffness-induced activation of hepatic stellate cells into tumor-promoting myofibroblasts. Gastroenterology 2018 154 8 2209 2221.e14 10.1053/j.gastro.2018.02.015 29454793
    [Google Scholar]
  31. Mederacke I. Hsu C.C. Troeger J.S. Huebener P. Mu X. Dapito D.H. Pradere J.P. Schwabe R.F. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun. 2013 4 1 2823 10.1038/ncomms3823 24264436
    [Google Scholar]
  32. Parth T. Shuang W. Scott L.F. The power of plasticity-metabolic regulation of hepatic stellate cells. Cell Metab. 2020 33 2 242 257 10.1016/j.cmet.2020.10.026 33232666
    [Google Scholar]
  33. Zhang J. Liu Y. Chen H. Yuan Q. Wang J. Niu M. Hou L. Gu J. Zhang J. MyD88 in hepatic stellate cells enhances liver fibrosis via promoting macrophage M1 polarization. Cell Death Dis. 2022 13 4 411 10.1038/s41419‑022‑04802‑z 35484116
    [Google Scholar]
  34. Liu X Xu J Rosenthal S Identification of lineage-specific transcription factors that prevent activation of hepatic stellate cells and promote fibrosis resolution. Gastroenterology 2020 158 6 1728 1744 10.1053/j.gastro.2020.01.027 31982409
    [Google Scholar]
  35. Inzaugarat M.E. Johnson C.D. Holtmann T.M. McGeough M.D. Trautwein C. Papouchado B.G. Schwabe R. Hoffman H.M. Wree A. Feldstein A.E. NLR family pyrin domain‐containing 3 inflammasome activation in hepatic stellate cells induces liver fibrosis in mice. Hepatology 2019 69 2 845 859 10.1002/hep.30252 30180270
    [Google Scholar]
  36. Crouchet E. Dachraoui M. Jühling F. Roehlen N. Oudot M.A. Durand S.C. Ponsolles C. Gadenne C. Meiss-Heydmann L. Moehlin J. Martin R. Brignon N. Del Zompo F. Teraoka Y. Aikata H. Abe-Chayama H. Chayama K. Saviano A. Heide D. Onea M. Geyer L. Wolf T. Felli E. Pessaux P. Heikenwälder M. Chambon P. Schuster C. Lupberger J. Mukherji A. Baumert T.F. Targeting the liver clock improves fibrosis by restoring TGF-β signaling. J. Hepatol. 2025 82 1 120 133 10.1016/j.jhep.2024.07.034 39173955
    [Google Scholar]
  37. Baghaei K. Mazhari S. Tokhanbigli S. Parsamanesh G. Alavifard H. Schaafsma D. Ghavami S. Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis. Drug Discov. Today 2022 27 4 1044 1061 10.1016/j.drudis.2021.12.012 34952225
    [Google Scholar]
  38. Tsuchida T. Friedman S.L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 2017 14 7 397 411 10.1038/nrgastro.2017.38 28487545
    [Google Scholar]
  39. Ezhilarasan D. Sokal E. Najimi M. Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets. Hepatobiliary Pancreat. Dis. Int. 2018 17 3 192 197 10.1016/j.hbpd.2018.04.003 29709350
    [Google Scholar]
  40. Nwosu Z.C. Alborzinia H. Wölfl S. Dooley S. Liu Y. Evolving insights on metabolism, autophagy, and epigenetics in liver myofibroblasts. Front. Physiol. 2016 7 191 10.3389/fphys.2016.00191 27313533
    [Google Scholar]
  41. Vienberg S. Geiger J. Madsen S. Dalgaard L.T. Micro RNA s in metabolism. Acta Physiol. 2017 219 2 346 361 10.1111/apha.12681 27009502
    [Google Scholar]
  42. Hochreuter M.Y. Dall M. Treebak J.T. Barrès R. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives. Mol. Metab. 2022 65 101581 10.1016/j.molmet.2022.101581 36028120
    [Google Scholar]
  43. Liu X. Ma H. Wu R. Wang H. Xu H. Li S. Wang G. Lv G. Niu J. Identification of liver fibrosis-related microRNAs in human primary hepatic stellate cells using high-throughput sequencing. Genes 2022 13 12 2201 10.3390/genes13122201 36553468
    [Google Scholar]
  44. Nijhuis A Biancheri P Lewis A In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts. Clin Sci 2014 127 5 341 350 10.1042/CS20140048 24641356
    [Google Scholar]
  45. Knabel M.K. Ramachandran K. Karhadkar S. Hwang H.W. Creamer T.J. Chivukula R.R. Sheikh F. Clark K.R. Torbenson M. Montgomery R.A. Cameron A.M. Mendell J.T. Warren D.S. Systemic delivery of scAAV8-encoded MiR-29a ameliorates hepatic fibrosis in carbon tetrachloride-treated mice. PLoS One 2015 10 4 e0124411 10.1371/journal.pone.0124411 25923107
    [Google Scholar]
  46. Peng W.J. Tao J.H. Mei B. Chen B. Li B.Z. Yang G.J. Zhang Q. Yao H. Wang B.X. He Q. Wang J. MicroRNA-29: A potential therapeutic target for systemic sclerosis. Expert Opin. Ther. Targets 2012 16 9 875 879 10.1517/14728222.2012.708339 22793265
    [Google Scholar]
  47. Horita M. Farquharson C. Stephen L.A. The role of miR‐29 family in disease. J. Cell. Biochem. 2021 122 7 696 715 10.1002/jcb.29896 33529442
    [Google Scholar]
  48. Zhang Y. Wu L. Wang Y. Zhang M. Li L. Zhu D. Li X. Gu H. Zhang C.Y. Zen K. Protective role of estrogen-induced miRNA-29 expression in carbon tetrachloride-induced mouse liver injury. J. Biol. Chem. 2012 287 18 14851 14862 10.1074/jbc.M111.314922 22393047
    [Google Scholar]
  49. Hyun J. Choi S.S. Diehl A.M. Jung Y. Potential role of Hedgehog signaling and microRNA-29 in liver fibrosis of IKKβ-deficient mouse. J. Mol. Histol. 2014 45 1 103 112 10.1007/s10735‑013‑9532‑5 23949847
    [Google Scholar]
  50. Pathania A.S. Chava H. Chaturvedi N.K. Chava S. Byrareddy S.N. Coulter D.W. Challagundla K.B. The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma. Cell Death Dis. 2024 15 6 428 10.1038/s41419‑024‑06791‑7 38890285
    [Google Scholar]
  51. Bernard M. Yang B. Migneault F. Turgeon J. Dieudé M. Olivier M.A. Cardin G.B. El-Diwany M. Underwood K. Rodier F. Hébert M.J. Autophagy drives fibroblast senescence through MTORC2 regulation. Autophagy 2020 16 11 2004 2016 10.1080/15548627.2020.1713640 31931659
    [Google Scholar]
  52. Yu X. Elfimova N. Müller M. Bachurski D. Koitzsch U. Drebber U. Mahabir E. Hansen H.P. Friedman S.L. Klein S. Dienes H.P. Hösel M. Buettner R. Trebicka J. Kondylis V. Mannaerts I. Odenthal M. Autophagy-related activation of hepatic stellate cells reduces cellular miR-29a by promoting its vesicular secretion. Cell. Mol. Gastroenterol. Hepatol. 2022 13 6 1701 1716 10.1016/j.jcmgh.2022.02.013 35219894
    [Google Scholar]
  53. Chang N.C. Autophagy and stem cells: Self-eating for self-renewal. Front. Cell Dev. Biol. 2020 8 138 10.3389/fcell.2020.00138 32195258
    [Google Scholar]
  54. Sotthibundhu A. Promjuntuek W. Liu M. Shen S. Noisa P. Roles of autophagy in controlling stem cell identity: A perspective of self-renewal and differentiation. Cell Tissue Res. 2018 374 2 205 216 10.1007/s00441‑018‑2829‑7 29696372
    [Google Scholar]
  55. Klionsky D.J. Petroni G. Amaravadi R.K. Baehrecke E.H. Ballabio A. Boya P. Bravo-San Pedro J.M. Cadwell K. Cecconi F. Choi A.M.K. Choi M.E. Chu C.T. Codogno P. Colombo M.I. Cuervo A.M. Deretic V. Dikic I. Elazar Z. Eskelinen E.L. Fimia G.M. Gewirtz D.A. Green D.R. Hansen M. Jäättelä M. Johansen T. Juhász G. Karantza V. Kraft C. Kroemer G. Ktistakis N.T. Kumar S. Lopez-Otin C. Macleod K.F. Madeo F. Martinez J. Meléndez A. Mizushima N. Münz C. Penninger J.M. Perera R.M. Piacentini M. Reggiori F. Rubinsztein D.C. Ryan K.M. Sadoshima J. Santambrogio L. Scorrano L. Simon H.U. Simon A.K. Simonsen A. Stolz A. Tavernarakis N. Tooze S.A. Yoshimori T. Yuan J. Yue Z. Zhong Q. Galluzzi L. Pietrocola F. Autophagy in major human diseases. EMBO J. 2021 40 19 e108863 10.15252/embj.2021108863 34459017
    [Google Scholar]
  56. Ho T.T. Warr M.R. Adelman E.R. Lansinger O.M. Flach J. Verovskaya E.V. Figueroa M.E. Passegué E. Autophagy maintains the metabolism and function of young and old stem cells. Nature 2017 543 7644 205 210 10.1038/nature21388 28241143
    [Google Scholar]
  57. Petersen M. Ebstrup E. Rodriguez E. Going through changes – The role of autophagy during reprogramming and differentiation. J. Cell Sci. 2024 137 4 jcs261655 10.1242/jcs.261655 38393817
    [Google Scholar]
  58. Perrotta C. Cattaneo M.G. Molteni R. De Palma C. Autophagy in the regulation of tissue differentiation and homeostasis. Front. Cell Dev. Biol. 2020 8 602901 10.3389/fcell.2020.602901 33363161
    [Google Scholar]
  59. Zhang Y. Liu W. Yuan W. Cai Z. Ye G. Zheng G. Xu C. Wang X. zeng C. Mi R. Feng P. Chen F. Wu Y. Shen H. Wang P. Impairment of APPL1/Myoferlin facilitates adipogenic differentiation of mesenchymal stem cells by blocking autophagy flux in osteoporosis. Cell. Mol. Life Sci. 2022 79 9 488 10.1007/s00018‑022‑04511‑y 35984564
    [Google Scholar]
  60. Chen Y. Li Q. Liu Y. Chen X. Jiang S. Lin W. Zhang Y. Liu R. Shao B. Chen C. Yuan Q. Zhou C. AFF4 regulates cellular adipogenic differentiation via targeting autophagy. PLoS Genet. 2022 18 9 e1010425 10.1371/journal.pgen.1010425 36149892
    [Google Scholar]
  61. Jaber F.A. Khan N.M. Ansari M.Y. Al-Adlaan A.A. Hussein N.J. Safadi F.F. Autophagy plays an essential role in bone homeostasis. J. Cell. Physiol. 2019 234 8 12105 12115 10.1002/jcp.27071 30820954
    [Google Scholar]
  62. Thoen L.F.R. Guimarães E.L. van Grunsven L.A. Autophagy: A new player in hepatic stellate cell activation. Autophagy 2012 8 1 126 128 10.4161/auto.8.1.18105 22082960
    [Google Scholar]
  63. Adam P. Jowita S. Magdalena J. Evaluation of liver fibrosis in patients with Wilson's disease. Eur J Gastroenterol Hepatol 2021 33 4 535 540 10.1097/MEG.0000000000001754 32433421
    [Google Scholar]
  64. Mi X. Song Y. Deng C. Yan J. Li Z. Li Y. Zheng J. Yang W. Gong L. Shi J. Stimulation of liver fibrosis by N2 neutrophils in Wilson’s disease. Cell. Mol. Gastroenterol. Hepatol. 2023 16 5 657 684 10.1016/j.jcmgh.2023.06.012 37406734
    [Google Scholar]
  65. Nehring P. Szeligowska J. Przybyłkowski A. Elastography of the liver in Wilson's disease. Diagnostics 2023 13 11 1898 10.3390/diagnostics13111898 37296749
    [Google Scholar]
  66. Chittampalli N.Y. Tianyue Q. Dipankar B. Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatotic liver disease. J. Hepatol. 2024 S0168-8278 24 00197 10.1016/j.jhep.2024.03.014
    [Google Scholar]
  67. Humeres C. Shinde A.V. Hanna A. Alex L. Hernández S.C. Li R. Chen B. Conway S.J. Frangogiannis N.G. Smad7 effects on TGF-β and ErbB2 restrain myofibroblast activation and protect from postinfarction heart failure. J. Clin. Invest. 2022 132 3 e146926 10.1172/JCI146926 34905511
    [Google Scholar]
  68. Hammerich L. Tacke F. Hepatic inflammatory responses in liver fibrosis. Nat. Rev. Gastroenterol. Hepatol. 2023 20 10 633 646 10.1038/s41575‑023‑00807‑x 37400694
    [Google Scholar]
  69. Ronen S. Fereshteh Y. Maya E. Boris H. The role of myofibroblasts in physiological and pathological tissue repair. Cold Spring Harb Perspect Biol 2023 15 1 a041231 10.1101/cshperspect.a041231 36123034
    [Google Scholar]
  70. Yang A.T. Kim Y.O. Yan X.Z. Abe H. Aslam M. Park K.S. Zhao X.Y. Jia J.D. Klein T. You H. Schuppan D. Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis. Cell. Mol. Gastroenterol. Hepatol. 2023 15 4 841 867 10.1016/j.jcmgh.2022.12.005 36521660
    [Google Scholar]
  71. Gong Y. Li Z. Zou S. Deng D. Lai P. Hu H. Yao Y. Hu L. Zhang S. Li K. Wei T. Zhao X. Xiao G. Chen Z. Jiang Y. Bai X. Zou Z. Vangl2 limits chaperone-mediated autophagy to balance osteogenic differentiation in mesenchymal stem cells. Dev. Cell 2021 56 14 2103 2120.e9 10.1016/j.devcel.2021.06.011 34214490
    [Google Scholar]
  72. Shao T. Ke H. Liu R. Xu L. Han S. Zhang X. Dang Y. Jiao X. Li W. Chen Z.J. Qin Y. Zhao S. Autophagy regulates differentiation of ovarian granulosa cells through degradation of WT1. Autophagy 2022 18 8 1864 1878 10.1080/15548627.2021.2005415 35025698
    [Google Scholar]
  73. Wang Y.Y. Jiang H. Pan J. Huang X.R. Wang Y.C. Huang H.F. To K.F. Nikolic-Paterson D.J. Lan H.Y. Chen J.H. Macrophage-to-myofibroblast transition contributes to interstitial fibrosis in chronic renal allograft injury. J. Am. Soc. Nephrol. 2017 28 7 2053 2067 10.1681/ASN.2016050573 28209809
    [Google Scholar]
  74. Wasilewicz R. Wasilewicz J. Pruszyńska-Oszmałek E. Stuper - Szablewska K. Leciejewska N. Kołodziejski P.A. Genistein stimulates the viability and prevents myofibroblastic transformation in human trabecular meshwork cells stimulated by TGF-β. Exp. Eye Res. 2024 240 109806 10.1016/j.exer.2024.109806 38272381
    [Google Scholar]
/content/journals/cmm/10.2174/0115665240373925250510072405
Loading
miRNA-29b-3p: An Important Target for Ameliorating Liver Fibrosis in Wilson Disease by Inhibiting Autophagy
Bentham Science Publishers ; https://doi.org/10.2174/0115665240373925250510072405
/content/journals/cmm/10.2174/0115665240373925250510072405
/content/journals/cmm/10.2174/0115665240373925250510072405
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: ULK1 ; miRNA-29b-3p ; HSCs ; Wilson disease ; myofibroblasts ; Autophagy ; Liver fibrosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test